Program Overview
This educational case escalation series is designed to improve your use of primary maintenance therapy for patients with advanced ovarian cancer through personalized and multidisciplinary treatment planning and adverse event management, as well as improved recognition of barriers to delivery of guideline-concordant care. This activity is comprised of 3 interactive, video-based modules that escalate in complexity. Each module includes a brief clinical primer, followed by case presentation and discussion. Throughout the modules, you will have the opportunity to share your approaches and perspectives, while watching the expert faculty provide evidence-based rationale for their own strategies. The activity also includes point-of-care resources such as personalized posters and video micromodules.
Kathleen N. Moore, MD, MS, FASCO
Deputy Director
Co-Director Cancer Therapeutics Program
Stephenson Cancer Center at OU Health
Professor, Gynecologic Oncology – University of Oklahoma, HSC
Oklahoma City, Oklahoma
Module 1: Basic Decision-Making
PROGRAM OVERVIEW
In module 1 of this case escalation series, Dr. Moore presents the case of a 56-year-old woman diagnosed with stage III high-grade serous ovarian cancer. Her discussion explores individualized maintenance therapy for women with advanced ovarian cancer, including diagnosis, germline testing, molecular subtyping, treatment selection (eg, PARP inhibition with or without bevacizumab), and the importance of shared decision making.
TARGET AUDIENCE
This activity is designed to meet the educational needs of gynecologic oncologists, medical oncologists, advanced healthcare practitioners, nurses, pharmacists, pathologists, and other members of the multidisciplinary care team involved in the management of advanced ovarian cancer.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Develop personalized treatment plans for front-line maintenance in patients with advanced ovarian cancer based on NCCN guidelines and supporting clinical data
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hour.
PHARMACISTS AND PHARMACY TECHNICIANS (ACPE) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 0.25 knowledge-based continuing pharmacy education (CPE) contact hours.
NOTE to pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a Med Learning Group–sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Kathleen N. Moore, MD, MS, FASCO | Consulting fee: Aadi, AbbVie, AstraZeneca, Blueprint, Corcept, Caris, BioNTech, Duality, Daiichi Sankyo, Eisai, Genentech/Roche, ImmunoGen, Janssen, Merck, Mersana, Regeneron, Schrödinger, Verastem, Takeda, Zymeworks, Zentalis Contracted research: AstraZeneca, Daiichi Sankyo, TORL, Verastem, Regeneron |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Kim L. Farina, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Shannon Mutch MS, RN, OCN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Abigail Dill, Program Manager for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture the faculty may mention the use of medications for both US Food and Drug Administration (FDA)-approved and non-FDA-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use their clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: May 21, 2025
EXPIRATION DATE: May 21, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited
Kathleen N. Moore, MD, MS, FASCO
Deputy Director
Co-Director Cancer Therapeutics Program
Stephenson Cancer Center at OU Health
Professor, Gynecologic Oncology – University of Oklahoma, HSC
Oklahoma City, Oklahoma
Module 2: Managing Toxicities Associated With PARP Inhibitor-Based Maintenance Therapy
PROGRAM OVERVIEW
In module 2 of this case escalation series, Dr. Moore presents the case of a 67-year-old woman with advanced ovarian cancer who experiences adverse events (AEs) while on PARP-inhibitor (PARPi) primary maintenance therapy. Her discussion explores the importance of patient counseling before initiation of and while receiving a PARPi, characteristic AEs associated with PARPi maintenance, their typical severity and time of onset, and clinical pearls for AE monitoring and mitigation.
TARGET AUDIENCE
This activity is designed to meet the educational needs of gynecologic oncologists, medical oncologists, advanced healthcare practitioners, nurses, pharmacists, pathologists, and other members of the multidisciplinary care team involved in the management of advanced ovarian cancer.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Develop personalized treatment plans for front-line maintenance in patients with advanced ovarian cancer based on NCCN guidelines and supporting clinical data
- Implement multidisciplinary best practices for prompt recognition and mitigation of toxicities associated with the use of PARP inhibitors in the maintenance setting of advanced ovarian cancer
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this activity for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.50 ANCC contact hour.
PHARMACISTS AND PHARMACY TECHNICIANS (ACPE) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 0.50 knowledge-based continuing pharmacy education (CPE) contact hours
NOTE to pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Kathleen N. Moore, MD, MS, FASCO | Consulting fee: Aadi, AbbVie, AstraZeneca, Blueprint, Corcept, Caris, BioNTech, Duality, Daiichi Sankyo, Eisai, Genentech/Roche, ImmunoGen, Janssen, Merck, Mersana, Regeneron, Schrödinger, Verastem, Takeda, Zymeworks, Zentalis Contracted research: AstraZeneca, Daiichi Sankyo, TORL, Verastem, Regeneron |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this continuing education (CE) activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Kim L. Farina, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Shannon Mutch MS, RN, OCN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Abigail Dill, Program Manager for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture the faculty may mention the use of medications for both US Food and Drug Administration (FDA)-approved and non-FDA-approved indications
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use their clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: May 21, 2025
EXPIRATION DATE: May 21, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited
Kathleen N. Moore, MD, MS, FASCO
Deputy Director
Co-Director Cancer Therapeutics Program
Stephenson Cancer Center at OU Health
Professor, Gynecologic Oncology – University of Oklahoma, HSC
Oklahoma City, Oklahoma
Module 3: Addressing Disparities in Care in Ovarian Cancer Through Multidisciplinary Care
PROGRAM OVERVIEW
In module 3 of this case escalation series, Dr. Moore presents the case of a 62-year-old woman facing barriers to care for her advanced ovarian cancer. Her discussion explores key disparities in care experienced by women with ovarian cancer, examples of their manifestations in healthcare, and how they can impact the receipt of optimal care. She shares her perspectives on the importance of recognizing barriers to care and helping patients overcome them.
TARGET AUDIENCE
This activity is designed to meet the educational needs of gynecologic oncologists, medical oncologists, advanced healthcare practitioners, nurses, pharmacists, pathologists, and other members of the multidisciplinary care team involved in the management of advanced ovarian cancer.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Develop personalized treatment plans for front-line maintenance in patients with advanced ovarian cancer based on NCCN guidelines and supporting clinical data
- Facilitate approaches to recognize and address inequities in ovarian cancer care through guideline-concordant management
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this activity for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.50 ANCC contact hour.
PHARMACISTS AND PHARMACY TECHNICIANS (ACPE) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 0.50 knowledge-based continuing pharmacy education (CPE) contact hours
NOTE to pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Kathleen N. Moore, MD, MS, FASCO | Consulting fee: Aadi, AbbVie, AstraZeneca, Blueprint, Corcept, Caris, BioNTech, Duality, Daiichi Sankyo, Eisai, Genentech/Roche, ImmunoGen, Janssen, Merck, Mersana, Regeneron, Schrödinger, Verastem, Takeda, Zymeworks, Zentalis Contracted research: AstraZeneca, Daiichi Sankyo, TORL, Verastem, Regeneron |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this continuing education (CE) activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Kim L. Farina, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Shannon Mutch MS, RN, OCN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Abigail Dill, Program Manager for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture the faculty may mention the use of medications for both US Food and Drug Administration (FDA)-approved and non-FDA-approved indications
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use their clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: May 21, 2025
EXPIRATION DATE: May 21, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited
